Royal Bank Of Canada Issues Pessimistic Forecast for Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price

Rhythm Pharmaceuticals (NASDAQ:RYTM) had its price target dropped by research analysts at Royal Bank Of Canada from $140.00 to $130.00 in a research note issued on Tuesday,Benzinga reports. The firm currently has an “outperform” rating on the stock. Royal Bank Of Canada’s price target suggests a potential upside of 51.41% from the company’s current price.

Several other brokerages have also recently weighed in on RYTM. Telsey Advisory Group set a $143.00 price target on Rhythm Pharmaceuticals in a research note on Thursday, March 12th. Bank of America dropped their target price on shares of Rhythm Pharmaceuticals from $145.00 to $139.00 and set a “buy” rating on the stock in a report on Tuesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Rhythm Pharmaceuticals in a research report on Thursday, January 22nd. Zacks Research upgraded shares of Rhythm Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 17th. Finally, HC Wainwright lowered their price target on shares of Rhythm Pharmaceuticals from $125.00 to $110.00 and set a “buy” rating for the company in a research report on Monday, March 2nd. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $131.13.

Rhythm Pharmaceuticals Stock Down 2.1%

Shares of RYTM opened at $85.86 on Tuesday. The stock has a market capitalization of $5.86 billion, a P/E ratio of -27.61 and a beta of 2.06. Rhythm Pharmaceuticals has a twelve month low of $45.90 and a twelve month high of $122.20. The firm has a fifty day simple moving average of $99.45 and a two-hundred day simple moving average of $102.69.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last issued its quarterly earnings data on Thursday, February 26th. The company reported ($0.73) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.79) by $0.06. The firm had revenue of $57.25 million for the quarter, compared to analyst estimates of $56.16 million. Rhythm Pharmaceuticals had a negative return on equity of 266.56% and a negative net margin of 103.57%.The business’s quarterly revenue was up 36.9% compared to the same quarter last year. During the same period last year, the company earned ($0.72) EPS. Sell-side analysts expect that Rhythm Pharmaceuticals will post -4.32 EPS for the current fiscal year.

Insider Activity at Rhythm Pharmaceuticals

In other news, CAO Christopher Paul German sold 5,614 shares of the firm’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $89.56, for a total value of $502,789.84. Following the transaction, the chief accounting officer directly owned 160 shares in the company, valued at $14,329.60. This trade represents a 97.23% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CFO Hunter C. Smith sold 4,385 shares of Rhythm Pharmaceuticals stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $101.26, for a total value of $444,025.10. Following the completion of the sale, the chief financial officer directly owned 110,512 shares of the company’s stock, valued at $11,190,445.12. The trade was a 3.82% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 27,267 shares of company stock valued at $2,719,955 over the last three months. 6.10% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Nisa Investment Advisors LLC increased its position in shares of Rhythm Pharmaceuticals by 956.9% during the 3rd quarter. Nisa Investment Advisors LLC now owns 13,254 shares of the company’s stock valued at $1,339,000 after purchasing an additional 12,000 shares during the last quarter. EFG Asset Management North America Corp. bought a new position in shares of Rhythm Pharmaceuticals in the 3rd quarter worth approximately $2,047,000. Penserra Capital Management LLC purchased a new position in shares of Rhythm Pharmaceuticals in the third quarter worth approximately $3,073,000. Hillsdale Investment Management Inc. bought a new stake in Rhythm Pharmaceuticals during the third quarter valued at approximately $4,302,000. Finally, Norges Bank bought a new stake in Rhythm Pharmaceuticals during the second quarter valued at approximately $13,105,000.

Key Stories Impacting Rhythm Pharmaceuticals

Here are the key news stories impacting Rhythm Pharmaceuticals this week:

• Positive Sentiment: Several major Wall Street firms lowered price targets but retained buy/overweight ratings, leaving substantial upside in consensus targets (new PTs reported in roughly the $100–$152 range). That continued analyst support may limit longer-term downdraft if management provides mitigating data or subgroup benefit. Analyst Reactions
• Positive Sentiment: A recent valuation piece argues that the stock’s pullback has improved entry valuation relative to its long-term return profile, suggesting some investors may view the decline as a buying opportunity if they believe in Rhythm’s broader franchise and pipeline. A Look At Rhythm Pharmaceuticals Valuation
• Neutral Sentiment: Rhythm released a transcript/slideshow discussing topline results and management insights from the Phase 3 EMANATE program; this provides more context but investors will need the full dataset and company guidance to reassess commercial and regulatory prospects. EMANATE Transcript & Slides
• Negative Sentiment: Multiple reports confirm Imcivree failed its late‑stage EMANATE weight‑loss trial for the targeted rare obesities, which directly increases near‑term clinical, regulatory and revenue uncertainty and was the primary driver of the share decline. Investors should watch for detailed efficacy/safety tables, any subgroup signals noted by management, and the company’s planned next steps. BioSpace: Imcivree Fails MSN: Trial Failure Coverage

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.